AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26086326 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention).
Number of subjects: 64
Study 26086326 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (IT) program for noCAD group.
Number of subjects: 64
Study 24810970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 0
Study 24810970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22341925 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus-eluting stent
Number of subjects: 6069
Study 22341925 — intervention group
Group type: COMPARATOR
Intervention: CYPHER sirolimus-eluting stent
Number of subjects: 6069
Study 22341925 — intervention group
Group type: COMPARATOR
Intervention: TAXUS stent
Number of subjects: 6069
Study 20357077 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 serving/d of pistachios (1 PD; 10% energy from pistachios; 30% total fat)
Number of subjects: 28
Study 20357077 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 servings/d of pistachios (2 PD; 20% energy from pistachios; 34% total fat)
Number of subjects: 28
Study 20357077 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 servings/d of pistachios (2 PD)
Number of subjects: 28
Study 20357077 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 serving/d of pistachios (1 PD)
Number of subjects: 28
Study 20357077 — intervention group
Group type: COMPARATOR
Intervention: Lower‐fat control diet without pistachios (25% total fat)
Number of subjects: 28
Study 17620510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow-derived progenitor cells (BMCs)
Number of subjects: 58
Study 17620510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 15668818 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (1 to 4 mg/day, mean dosage 1.45±0.08 mg/day)
Number of subjects: 77
Study 15668818 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (open-label treatment after 4 weeks)
Number of subjects: 77
Study 15668818 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initial treatment for 4 weeks)
Number of subjects: 77
Study 15668818 — intervention group
Group type: COMPARATOR
Intervention: Placebo switched to open-label risperidone
Number of subjects: 77
Study 11876001 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial therapy (ABT) in 30-34 week neonates
Number of subjects: 65
Study 11876001 — intervention group
Group type: COMPARATOR
Intervention: No antibacterial therapy (ABT) in 30-34 week neonates
Number of subjects: 65
Study 11876001 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial therapy (ABT) in neonates < 30 weeks
Number of subjects: 65
Study 10098560 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult and Child Surveys
Number of subjects: 0
Study 10098560 — intervention group
Group type: COMPARATOR
Intervention: Only Child Survey
Number of subjects: 0
Study 10098560 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Adult and Child Surveys
Number of subjects: 0
Study 7586114 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0/0)
Number of subjects: 175
Study 7586114 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg at 21:00 and placebo at 06:30 (150/0)
Number of subjects: 175
Study 7586114 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg at 21:00 and 06:30 (150/150)
Number of subjects: 175
Study 7586114 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg at 21:00 and placebo at 06:30 (300/0)
Number of subjects: 175
Study 7586114 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo at 21:00 and nizatidine 300 mg at 06:30 (0/300)
Number of subjects: 175
Study 7586114 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg at 21:00 and 06:30 (300/300)
Number of subjects: 175
Study 7586114 — intervention group
Group type: COMPARATOR
Intervention: Control group (0/0)
Number of subjects: 175
Study 7586114 — intervention group
Group type: EXPERIMENTAL
Intervention: 0/150, 150/150, 0/300, and 300/300 groups
Number of subjects: 175
Study 1703655 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised form of Phenytoinum "Polfa"
Number of subjects: 15
Study 1703655 — intervention group
Group type: COMPARATOR
Intervention: Foreign drug
Number of subjects: 15
Study 7410574 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist with 80% similar attitudes
Number of subjects: 128
Study 7410574 — intervention group
Group type: COMPARATOR
Intervention: Therapist with 20% similar attitudes
Number of subjects: 128
Study 29226799 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based cognitive-behavioral depression prevention program (DISA), presented once per week for 10 weeks.
Number of subjects: 462
Study 29226799 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what the control intervention was).
Number of subjects: 462
Study 28131530 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin dosing algorithm based on estimated glomerular filtration rate from cystatin C levels (eGFRcr‐cys)
Number of subjects: 399
Study 28131530 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin dosing algorithm based on estimated creatinine clearance (eCLcr) using the Cockcroft‐Gault formula
Number of subjects: 399
Study 25832738 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-point scale (forced choice)
Number of subjects: 0
Study 25832738 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-point scale with a 'neither' mid-point
Number of subjects: 0
Study 25832738 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-point scale with 'no opinion' option
Number of subjects: 0
Study 24169062 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal aerosol at 320 micrograms once daily
Number of subjects: 374
Study 24169062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 21454393 — intervention group
Group type: EXPERIMENTAL
Intervention: APD-A
Number of subjects: 25
Study 21454393 — intervention group
Group type: COMPARATOR
Intervention: APD-C
Number of subjects: 25
Study 19570573 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b (200 microg, subcutaneously, three times per week)
Number of subjects: 826
Study 19570573 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent to interferon gamma-1b)
Number of subjects: 826
Study 19570573 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma-1b
Number of subjects: 826
Study 19570573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 826
Study 17344505 — intervention group
Group type: EXPERIMENTAL
Intervention: Viable probiotics
Number of subjects: 28
Study 17344505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 17344505 — intervention group
Group type: COMPARATOR
Intervention: Probiotic sonicates
Number of subjects: 28
Study 15061268 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated LVEF calculation using GBPS
Number of subjects: 22
Study 15061268 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual LVEF calculation using GBPS
Number of subjects: 22
Study 15061268 — intervention group
Group type: COMPARATOR
Intervention: Comparison of manual and automated GBPS LVEF calculations
Number of subjects: 22
Study 11594897 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based methadone maintenance from primary care physicians (n = 22)
Number of subjects: 47
Study 11594897 — intervention group
Group type: COMPARATOR
Intervention: Usual care at an NTP (n = 24)
Number of subjects: 47
Study 9767357 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 fatty acids (4.8 g daily)
Number of subjects: 41
Study 9767357 — intervention group
Group type: COMPARATOR
Intervention: Antioxidants (150 mg of vitamin C, 75 mg of vitamin E and 15 mg of beta‐carotene daily)
Number of subjects: 41
Study 9767357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 8311284 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.015, 0.03, 0.045, or 0.06 mg/kg
Number of subjects: 56
Study 8311284 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.125, 0.25, 0.75, or 1 mg/kg
Number of subjects: 56
Study 8311284 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 56
Study 8311284 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium
Number of subjects: 56
Study 8311284 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine vs Edrophonium
Number of subjects: 56
Study 3613578 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol administration
Number of subjects: 9
Study 3613578 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control
Number of subjects: 9
Study 31595608 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate 58.8 mg
Number of subjects: 18
Study 31595608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29927865 — intervention group
Group type: EXPERIMENTAL
Intervention: Health worker training on the 'Ten Steps for Healthy Feeding for Children from Birth to Two Years of age' (n = 206)
Number of subjects: 387
Study 29927865 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 181)
Number of subjects: 387
Study 29927865 — intervention group
Group type: EXPERIMENTAL
Intervention: Health worker training (intervention)
Number of subjects: 387
Study 27055417 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily colchicine dosage
Number of subjects: 92
Study 27055417 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily colchicine dosage
Number of subjects: 92
Study 26683473 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 month, individually tailored weight maintenance intervention
Number of subjects: 0
Study 23608920 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib administered in nonmicronized form (larger particle size) under fasting conditions
Number of subjects: 28
Study 23608920 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib administered in HPMC capsules
Number of subjects: 28
Study 23608920 — intervention group
Group type: COMPARATOR
Intervention: Dabrafenib administered in gelatin capsules
Number of subjects: 28
Study 23608920 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib administered under fasting conditions
Number of subjects: 28
Study 15920417 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid resuscitation (Parkland formula)
Number of subjects: 31
Study 15920417 — intervention group
Group type: COMPARATOR
Intervention: Plasma resuscitation
Number of subjects: 31
Study 12183009 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 17
Study 12183009 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 17
Study 10521168 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 0
Study 10521168 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 8808216 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.125 microgram/day
Number of subjects: 45
Study 8808216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 1961961 — intervention group
Group type: EXPERIMENTAL
Intervention: Room-temperature (17-24 degrees C) thermodilution
Number of subjects: 20
Study 1961961 — intervention group
Group type: COMPARATOR
Intervention: Cold (5 degrees C) thermodilution
Number of subjects: 20
Study 6789008 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN) at 35 calories/kgm/day for at least 14 days postoperatively.
Number of subjects: 69
Study 6789008 — intervention group
Group type: COMPARATOR
Intervention: Customary enteral alimentation by feeding tubes (Control).
Number of subjects: 69
Study 31441801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac electrophysiological procedures without analgosedation
Number of subjects: 101
Study 31441801 — intervention group
Group type: COMPARATOR
Intervention: Low-dose midazolam
Number of subjects: 101
Study 31441801 — intervention group
Group type: COMPARATOR
Intervention: Patient-staff interaction mode
Number of subjects: 101
Study 31441801 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial factors (depressive, anxiety, somatic symptom scales)
Number of subjects: 101
Study 28520774 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor mountain hiking
Number of subjects: 42
Study 28520774 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor treadmill walking
Number of subjects: 42
Study 28520774 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control situation
Number of subjects: 42
Study 26387707 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention materials (annual newsletter)
Number of subjects: 41482
Study 26387707 — intervention group
Group type: COMPARATOR
Intervention: Token gift or birthday card
Number of subjects: 41482
Study 26387707 — intervention group
Group type: COMPARATOR
Intervention: Use of a secure website for study forms
Number of subjects: 41482
Study 23468866 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosigne®
Number of subjects: 57
Study 23468866 — intervention group
Group type: COMPARATOR
Intervention: Botox®
Number of subjects: 57
Study 21571703 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised high‐intensity progressive resistance exercise training (PRT) for 16 weeks
Number of subjects: 58
Study 21571703 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 29)
Number of subjects: 58
Study 19292215 — intervention group
Group type: EXPERIMENTAL
Intervention: Screw fixation (2 x 6.5‐mm cancellous screws)
Number of subjects: 116
Study 19292215 — intervention group
Group type: COMPARATOR
Intervention: Screwless fixation
Number of subjects: 116
Study 16997300 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis group (IVF-ET)
Number of subjects: 60
Study 16997300 — intervention group
Group type: COMPARATOR
Intervention: Tubal infertility group (IVF-ET)
Number of subjects: 60
Study 12799786 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent-protected angioplasty (SPAC)
Number of subjects: 350
Study 12799786 — intervention group
Group type: COMPARATOR
Intervention: Endarterectomy (CEA)
Number of subjects: 350
Study 11044229 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 35
Study 11044229 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 35
Study 11990135 — intervention group
Group type: COMPARATOR
Intervention: TE subjects (terminated early) at 18 degrees C
Number of subjects: 0
Study 11990135 — intervention group
Group type: COMPARATOR
Intervention: TE subjects (terminated early) at 22 degrees C
Number of subjects: 0
Study 11990135 — intervention group
Group type: COMPARATOR
Intervention: TE subjects (terminated early) at 26 degrees C
Number of subjects: 0
Study 11990135 — intervention group
Group type: COMPARATOR
Intervention: TE subjects (terminated early)
Number of subjects: 0
Study 8375835 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent regular use criteria (any past period of daily or weekly use plus any use during the 30 days before hospitalization)
Number of subjects: 474
Study 8375835 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-III-R substance use diagnoses
Number of subjects: 474
Study 8375835 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent regular use criteria
Number of subjects: 474
Study 8375835 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients identified by both methods
Number of subjects: 474
Study 3025388 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein diets (25% replacement with soy flour, soy concentrate, or soy isolate)
Number of subjects: 8
Study 3025388 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isolate as the main protein source
Number of subjects: 8
Study 3025388 — intervention group
Group type: COMPARATOR
Intervention: Meat protein diet
Number of subjects: 8
Study 28437283 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Educational Program (EEP)
Number of subjects: 42
Study 28437283 — intervention group
Group type: COMPARATOR
Intervention: Standard Institutional Instruction
Number of subjects: 42
Study 27609058 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy or uterine preservation procedure (Uterine Trial)
Number of subjects: 0
Study 27609058 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal sacrospinous fixation or abdominal sacrocolpopexy (Vault Trial)
Number of subjects: 0
Study 23919920 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic mixture (two Lactobacillus strains, one Bifidobacterium strain, one Propionibacterium strain and galacto‐oligosaccharides (32 g/l))
Number of subjects: 52
Study 23919920 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 52
Study 22353614 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg/d)
Number of subjects: 46
Study 22353614 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg/d)
Number of subjects: 46
Study 20864072 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise program with an elastic band (EG)
Number of subjects: 64
Study 20864072 — intervention group
Group type: COMPARATOR
Intervention: Control group not submitted to the exercise program (CG)
Number of subjects: 64
Study 18758308 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance irinotecan therapy (100 mg/m IV on days 1, 8, and 15, every 4 weeks up to six cycles)
Number of subjects: 120
Study 18758308 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 120
Study 15930237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention to lower saturated-fat and cholesterol intake
Number of subjects: 663
Study 15930237 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 663
Study 15930237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 663
Study 12822636 — intervention group
Group type: COMPARATOR
Intervention: Standard steel-tip end-hole cannula (7.3 mm)
Number of subjects: 9
Study 12822636 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft-Flow cannula (8.0 mm)
Number of subjects: 9
Study 12822636 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersion cannula (8.0 mm)
Number of subjects: 9
Study 10803042 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists and angiotensin-converting-enzyme inhibitors
Number of subjects: 0
Study 10803042 — intervention group
Group type: COMPARATOR
Intervention: Conventional antihypertensive drugs (beta-blockers or diuretics)
Number of subjects: 0
Study 10803042 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 8644803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine TGF‐beta 2 with air
Number of subjects: 150
Study 8644803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine TGF‐beta 2 with 5% perfluoropropane
Number of subjects: 150
Study 8644803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine TGF‐beta 2 with 10% perfluoropropane
Number of subjects: 150
Study 8644803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine TGF‐beta 2 with 16% perfluoropropane
Number of subjects: 150
Study 8644803 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant TGF‐beta 2
Number of subjects: 150
Study 8644803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 1992963 — intervention group
Group type: COMPARATOR
Intervention: 14 mg/kg per day of oral cyclosporine for 4 weeks (Group 1)
Number of subjects: 49
Study 1992963 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg per day of oral cyclosporine for 1 to 3 months (Group 2)
Number of subjects: 49
Study 1992963 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data for both groups for the first 4 weeks of therapy
Number of subjects: 49
Study 6336878 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise intervention
Number of subjects: 733
Study 6336878 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise intervention (with reinfarction included)
Number of subjects: 733
Study 31004837 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHEAR
Number of subjects: 10
Study 31004837 — intervention group
Group type: COMPARATOR
Intervention: BCDS
Number of subjects: 10
Study 28414020 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex community-based intervention to reduce alcohol consumption, including face-to-face sessions and text messages.
Number of subjects: 69
Study 28414020 — intervention group
Group type: COMPARATOR
Intervention: Active control in the form of a conventional alcohol brief intervention.
Number of subjects: 69
Study 26868949 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention delivered by a practice nurse or healthcare assistant
Number of subjects: 350
Study 26868949 — intervention group
Group type: COMPARATOR
Intervention: Standard care offered in General Practice
Number of subjects: 350
Study 25096168 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel/carboplatin (PCw) - paclitaxel 90mg/m², cisplatin 70mg/m² or carboplatin AUC 4
Number of subjects: 267
Study 25096168 — intervention group
Group type: COMPARATOR
Intervention: Three-weekly paclitaxel/carboplatin (PC3w) - paclitaxel 175mg/m², cisplatin 75mg/m² or carboplatin AUC 6
Number of subjects: 267
Study 25096168 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 267
Study 21696933 — intervention group
Group type: EXPERIMENTAL
Intervention: E0.25 (esmolol 0.25 mg/kg)
Number of subjects: 200
Study 21696933 — intervention group
Group type: EXPERIMENTAL
Intervention: E0.5 (esmolol 0.5 mg/kg)
Number of subjects: 200
Study 21696933 — intervention group
Group type: EXPERIMENTAL
Intervention: E1.0 (esmolol 1.0 mg/kg)
Number of subjects: 200
Study 21696933 — intervention group
Group type: COMPARATOR
Intervention: Control (E0 - no esmolol)
Number of subjects: 200
Study 19563327 — intervention group
Group type: EXPERIMENTAL
Intervention: IMZ implant system (two-stage cylinder type)
Number of subjects: 30
Study 19563327 — intervention group
Group type: EXPERIMENTAL
Intervention: Brånemark implant system (two-stage screw type)
Number of subjects: 30
Study 19563327 — intervention group
Group type: EXPERIMENTAL
Intervention: ITI implant system (one-stage screw type)
Number of subjects: 30
Study 19563327 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study 18154126 — intervention group
Group type: EXPERIMENTAL
Intervention: Local ultrasound hyperthermia (41-45 deg.C, TTD-36 Gy)
Number of subjects: 174